hUC‐MSC Combined with DHEA Alleviates Ovarian Senescence in Naturally Aging Mice through Enhancing Antioxidant Capacity and Inhibiting Inflammatory Response

• Published in: Stem cells international Vol. 2024; no. 1; p. 3100942
• Main Authors: Guan, Chun-Yi, Zhang, Dan, Sun, Xue-Cheng, Ma, Xu, Xia, Hong-Fei
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 2024; Wiley
• Subjects: 1-Phosphatidylinositol 3-kinase; 17β-Estradiol; Aging; AKT protein; Antibodies; Antioxidants; Cartilage; Dehydroepiandrosterone; Estradiol; Experiments; Females; Follicle-stimulating hormone; Follicles; Gametocytes; Health aspects; Inflammation; Inflammatory response; Life span; Ovaries; Proteins; Reactive oxygen species; Recovery of function; Reproductive status; Senescence; Sex hormones; Statistical analysis; Stem cells; Survival; TOR protein; Transplants & implants; Tumor necrosis factor-TNF; Tumor necrosis factor-α; Umbilical cord; Veins & arteries; United Kingdom; China; Beijing China; Canada; United Kingdom > UK; United States > US
• ISSN: 1687-966X; 1687-9678; 1687-9678
• DOI: 10.1155/2024/3100942

The ovary is an important organ for women to maintain reproductive and endocrine functions. Ovarian aging can lead to female reproductive aging, which is a key factor causing rapid aging of the female body. Umbilical cord‐derived MSCs (UC‐MSCs) play a therapeutic role in various degenerative diseases. Dehydroepiandrosterone (DHEA) is widely used in the treatment of reversing oocyte quality. However, it is unclear whether UC‐MSCs combined with DHEA supplementation can improve ovarian senescence in naturally aging mice. To address this question, we studied the influence of the combination of human UC‐MSCs (hUC‐MSCs) and DHEA on ovarian morphology and function in naturally aging mice. The results showed a significant augmentation in the number of primary follicles, as well as a significant upregulation of estradiol (E2), follicle‐stimulating hormone (FSH), and anti‐Mullerian hormone (AMH) hormone levels, and a significant increase in survival rate in naturally aging mice treated by hUC‐MSCs and DHEA. Moreover, the combination of hUC‐MSCs and DHEA significantly reduced the reactive oxygen species (ROS) level and downregulated the expression levels of proinflammatory factors IL‐6, IL‐18, and TNF‐ α . Furthermore, the PI3K/AKT/mTOR pathway was inhibited. Conclusively, the combination therapy of hUC‐MSC + DHEA contributed to restore ovarian function in aging mice and extend their lifespan by restoring hormone levels and inhibiting inflammatory factors.